WORK Medical Technology Group LTD (WOK) AI Stock Analysis

• Market Cap: $1.73M
• Dividend Yield: N/A
• Average Volume (3M): 33.96M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.97
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 216
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 1,219,255
• 10 Day Avg. Volume: 36,631,792
• 30 Day Avg. Volume: 33,957,643
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.12
• Price to Sales (P/S): 0.22
• P/FCF Ratio: 0.44
• Enterprise Value/Market Cap: 1.37
• Enterprise Value/Revenue: 0.24
• Enterprise Value/Gross Profit: 1.01
• Enterprise Value/Ebitda: -1.70
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: $1.50 ▼(-28.57% Downside)

The score is held down primarily by deteriorated financial performance (shrinking revenue and ongoing losses) and weak technical momentum (bearish MACD with price below key averages). Improved leverage and a rebound to positive operating/free cash flow provide some support, but valuation is constrained by negative earnings and no dividend data.

Positive Factors

Improved leverage

A materially lower debt-to-equity (~0.35 in 2025) reduces balance-sheet risk and interest burden, improving financial flexibility. This durable improvement supports funding R&D and commercialization initiatives without urgent refinancing, strengthening the company’s capacity to weather operational volatility.

Rebound to positive cash flow

Generative operating cash flow (~$6.2M) and free cash flow (~$4.9M) in 2025 demonstrate the business can internally fund operations and investments. If sustained, this improves self‑funding for product rollout, reduces reliance on dilutive financing, and enhances long‑term operational resilience.

Regulatory approval and distribution

Receiving manufacturing approval and securing an exclusive East China distribution (with RMB10M minimum target) for the AI-Automated Blood Cell Morphology Analyzer are structural milestones. They create a regulatory-compliant product and a committed commercial channel, materially improving commercialization prospects over the medium term.

Negative Factors

Shrinking revenue and negative margins

Persistent top-line decline (2025 revenue down ~8% and well below 2020–21 levels) combined with negative net margins (~-11%) indicate shrinking market traction and weak profitability. Structurally, this limits scale economies, reduces reinvestment capacity, and makes sustained margin recovery more challenging.

Cash-flow volatility

Marked volatility in operating and free cash flow, despite a 2025 rebound, undermines predictability of internal funding. This structural inconsistency raises financing risk for ongoing R&D and commercialization, increasing reliance on external capital at times when access or terms may be unfavorable.

Insider voting consolidation

A transaction that boosts the COO’s voting power to ~54.96% concentrates control and creates lasting governance risk. Entrenched insider control can reduce minority influence on strategy, increase the risk of self‑dealing or decisions that prioritize control retention over minority shareholder value.

WORK Medical Technology Group LTD Business Overview & Revenue Model

Company Description

WORK Medical Technology Group LTD, together with its subsidiaries, manufactures and sells medical consumables in the People's Republic of China and internationally. The company offers disposable medical devices, such as medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, and guedel airways, etc.; disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kits, oxygen face masks, heat and moisture exchanging filters, anesthesia masks, laryngoscope blades, suction sets, and nasal oxygen cannulas; other medical devices, such as KN95 masks and filtering half mask; and visualized prostatic dilatation catheters. It also exports its products to approximately 30 countries in Asia, Africa, Europe, North America, South America, and Oceania. WORK Medical Technology Group LTD was founded in 2002 and is based in Hangzhou City, China.

How the Company Makes Money

WORK Medical Technology Group LTD generates revenue through multiple streams, primarily from the sale of its medical devices and digital health solutions. The company sells its products to hospitals, clinics, and healthcare providers, which constitutes a significant portion of its income. Additionally, WOK earns revenue through subscription services associated with its telehealth platforms, allowing healthcare providers to offer remote care solutions. Partnerships with healthcare institutions and technology companies also play a crucial role in expanding its market reach and driving sales. Furthermore, WOK may engage in research collaborations and grants that contribute to its funding and innovation efforts, enhancing its overall earnings potential.

WORK Medical Technology Group LTD Financial Statement Overview

Summary

Fundamentals remain pressured: revenue has been shrinking for several years and profitability is still negative (loss-making with weak margins). Offsetting this, leverage improved materially (lower debt-to-equity) and 2025 cash flow rebounded to positive operating and free cash flow, but historical cash-flow volatility raises sustainability risk.

Income Statement

Profitability has deteriorated materially versus earlier years. Revenue has been shrinking for several years (2025 annual revenue down ~8% year over year and far below 2020–2021 levels), and the company is currently loss-making (2025 net margin about -11% and negative operating profit). The positive sign is a sharp improvement from 2024’s much deeper loss, with EBITDA turning slightly positive in 2025, but margins remain weak and the top-line trajectory is still a clear headwind.

Balance Sheet

Leverage looks more manageable in the latest year, with debt-to-equity improving to ~0.35 in 2025 (down from ~1.02 in 2024), suggesting reduced balance-sheet risk versus the prior year. Equity remains meaningful relative to assets, but returns are currently negative due to net losses (2025 return on equity around -6%), indicating the balance sheet is stable yet not being translated into attractive shareholder returns.

Cash Flow

Cash generation improved significantly in 2025, with strong positive operating cash flow (~$6.2M) and positive free cash flow (~$4.9M) after a very weak 2024. However, cash-flow consistency is a concern: operating and free cash flow have been volatile across the period (several negative years), and 2025 free-cash-flow growth is sharply negative versus the prior year’s reported base, highlighting uneven conversion and higher uncertainty around sustainability.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	9.85M	9.85M	11.51M	13.57M	19.71M	45.86M
Gross Profit	2.34M	2.34M	2.87M	4.14M	4.42M	8.64M
EBITDA	-1.39M	339.37K	-1.71M	2.08M	4.72M	11.87M
Net Income	-1.07M	-1.07M	-3.49M	112.03K	865.21K	5.96M
Balance Sheet
Total Assets	33.16M	33.16M	36.25M	29.96M	25.54M	30.66M
Cash, Cash Equivalents and Short-Term Investments	4.09M	4.09M	6.56M	1.60M	731.18K	508.71K
Total Debt	6.45M	6.45M	13.47M	9.10M	6.30M	6.60M
Total Liabilities	11.99M	11.99M	20.18M	18.97M	14.35M	19.26M
Stockholders Equity	18.35M	18.35M	13.19M	9.88M	10.00M	10.04M
Cash Flow
Free Cash Flow	4.91M	4.91M	-11.49M	1.63M	-4.27M	-7.24M
Operating Cash Flow	6.24M	6.24M	-2.23M	2.21M	-2.26M	-7.18M
Investing Cash Flow	-5.85M	-7.61M	-9.06M	-583.30K	-1.35M	-60.00K
Financing Cash Flow	-4.42M	-898.21K	15.66M	-728.72K	3.57M	7.99M

WORK Medical Technology Group LTD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.10
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WOK, the sentiment is Negative. The current price of 2.1 is above the 20-day moving average (MA) of 2.01, below the 50-day MA of 136.61, and below the 200-day MA of 4066.44, indicating a bearish trend. The MACD of -34.76 indicates Negative momentum. The RSI at 28.12 is Positive, neither overbought nor oversold. The STOCH value of 16.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WOK.

WORK Medical Technology Group LTD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKSO	54 Neutral	$31.79M	-1.63	-85.01%	―	-16.59%	43.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WOK	44 Neutral	$1.73M	-0.01	―	―	―	―
LUCY	43 Neutral	$5.99M	-0.43	-74.10%	―	53.22%	72.69%
GCTK	42 Neutral	$1.78M	>-0.01	―	―	―	60.83%

WORK Medical Technology Group LTD Corporate Events

WORK Medical Technology Group Sells New Class B Shares to COO’s Entity, Consolidating Voting Control

On December 30, 2025, WORK Medical Technology Group LTD entered into a securities purchase agreement with LWY GROUP LTD, an existing shareholder wholly owned by the company’s chief operating officer, Baiming Yu, for the issuance and sale of 100,000 Class B ordinary shares at an aggregate purchase price of $500,000 under Regulation S of the U.S. Securities Act of 1933. The transaction, which was approved by the company’s audit committee and full board and is expected to close on or about January 13, 2026, will increase Yu’s beneficial holdings to 100,625 Class B shares, representing approximately 54.96% of the company’s total voting power, thereby consolidating insider control and potentially shaping future corporate governance and strategic direction for shareholders.

The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.

WORK Medical Technology Group Executes 100-for-1 Share Consolidation to Maintain Nasdaq Listing

On October 21, 2025, WORK Medical Technology Group LTD shareholders approved resolutions authorizing one or more consolidations of the company’s authorized, issued and outstanding ordinary shares within a range of 2:1 to 250:1, along with adopting an amended and restated memorandum of association to reflect any such changes. Following this approval, the board resolved on November 29, 2025 to implement a 100:1 share consolidation, which took effect on December 29, 2025, reducing the company’s outstanding ordinary shares from about 122.0 million to approximately 1.22 million and similarly consolidating its authorized share capital, with fractional shares rounded up and electronic holdings adjusted automatically, in order to raise the per-share price and allow the company to more quickly regain compliance with Nasdaq’s minimum bid price requirement and reduce the risk of delisting; the Class A ordinary shares continue to trade on Nasdaq under the symbol “WOK” with a new CUSIP.

The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.

WORK Medical Technology Group Enters Sales Agreement to Raise $200 Million

On November 20, 2025, WORK Medical Technology Group LTD announced a new sales agreement with AC Sunshine Securities, LLC, allowing the company to offer and sell Class A ordinary shares through the sales agent. The agreement enables the company to raise up to $200 million, with shares sold at the company’s discretion, reflecting a strategic move to enhance market liquidity and financial flexibility. This development could potentially impact the company’s market position and provide stakeholders with opportunities for investment.

The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.

WORK Medical Technology Group Approves Key Resolutions at Extraordinary General Meeting

On November 7, 2025, WORK Medical Technology Group LTD held an Extraordinary General Meeting of Shareholders in Hangzhou, China, where key resolutions were adopted. These included a share capital increase, amendments to the company’s memorandum and articles of association, and approval of potential share consolidations. The resolutions aim to enhance the company’s financial structure and operational flexibility, potentially impacting its market positioning and shareholder value.

The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.

WORK Medical Technology Group LTD Regains Nasdaq Compliance

WORK Medical Technology Group LTD has successfully regained compliance with the Nasdaq Minimum Bid Price Requirement as of November 4, 2025. This compliance was achieved by maintaining a minimum closing bid price of $1.00 or greater for its Class A Ordinary Shares over a consecutive 10-day period, effectively closing the matter with Nasdaq and stabilizing its market position.

The most recent analyst rating on (WOK) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on WORK Medical Technology Group LTD stock, see the WOK Stock Forecast page.